Form 4: Neuronetics CFO Granted 400,000 Restricted Stock Units in Future-Dated Award

Steven Pfanstiel, EVP, CFO, and Treasurer of Neuronetics, Inc., was granted 400,000 restricted stock units (RSUs) on July 15, 2025, as part of an equity compensation plan.

Summary

• Steven Pfanstiel, the Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc. (STIM), was granted a total of 400,000 Restricted Stock Units (RSUs).
• The RSU grants were made on July 15, 2025, and were executed pursuant to a Rule 10b5-1(c) plan.
• The first award consists of 200,000 RSUs, which will vest in three equal annual installments beginning on July 15, 2026.
• The second award also consists of 200,000 RSUs, which will vest in three equal annual installments beginning on July 15, 2027.
• Each RSU represents a contingent right to receive one share of Neuronetics' common stock.
• The acquisition price for these RSUs was $0, which is typical for equity grants.
• Following these reported transactions, Steven Pfanstiel beneficially owns 400,000 shares directly.

Sentiment

Score: 7

Explanation: The grant of a significant number of restricted stock units to a key executive like the CFO is generally positive as it aligns management's interests with long-term shareholder value and aids in executive retention. However, it also represents potential future dilution.

Positives

• The grant of 400,000 Restricted Stock Units to a key executive like the CFO aligns management's long-term interests with those of shareholders.
• The multi-year vesting schedule encourages the CFO's continued service and commitment to the company's future performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and compliant equity compensation strategy.

Negatives

• The RSU grants represent potential future dilution for existing shareholders when the units vest and convert into common stock.
• There is no immediate cash inflow for the executive from the grant itself, as the value is realized upon vesting and conversion.

Risks

• Vesting of the RSUs is contingent upon the Reporting Person's continuous service through the specified vesting dates, meaning the executive must remain employed to receive the shares.
• Future conversion of RSUs into common stock will increase the total number of outstanding shares, potentially leading to dilution of existing shareholder value.

Future Outlook

The vesting schedule for the RSU awards extends into 2026 and 2027, indicating a long-term incentive structure designed to retain the CFO and align his performance with the company's future success.

Industry Context

Equity compensation, particularly through Restricted Stock Units, is a common and widely accepted practice in the medical technology and broader corporate sectors. This method is frequently used to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance and shareholder value of the company. This grant is consistent with standard executive compensation practices observed across the industry.

Comparison to Industry Standards

• The grant of restricted stock units to a key executive like the CFO is a standard practice across publicly traded companies, particularly in the medical technology sector, to incentivize long-term performance and retention.
• While specific comparable companies are not detailed in this filing, similar RSU grants are common for executives at companies like Medtronic, Boston Scientific, or Stryker, often tied to performance metrics or time-based vesting schedules.
• The use of a Rule 10b5-1(c) plan for such grants is also a standard compliance measure, demonstrating a pre-planned and transparent approach to insider transactions.

Stakeholder Impact

• Shareholders: Potential for future dilution upon RSU conversion, but also benefit from enhanced alignment of executive incentives with long-term company performance.
• Management (Steven Pfanstiel): Receives significant long-term equity compensation, incentivizing continued service and performance.

Next Steps

• Vesting of the first 200,000 RSU award is scheduled to commence on July 15, 2026, in three equal annual installments.
• Vesting of the second 200,000 RSU award is scheduled to commence on July 15, 2027, in three equal annual installments.

Key Dates

Recommendation

Keywords

Neuronetics, STIM, Restricted Stock Units, RSU, Equity Compensation, Executive Compensation, Form 4, SEC Filing, Steven Pfanstiel, CFO, Insider Transaction, Corporate Governance